Alkermes (ALKS) vs Praxis Precision Medicines (PRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Alkermes (ALKS) over the past year, gaining 434.2% versus a gain of 33.9%. Over five years, ALKS leads with a +30.9% price change compared with -7.4% for PRAX. Praxis Precision Medicines is the larger company by market cap ($7.76 billion vs $6.95 billion), about 1.1 times the size, while Alkermes is growing revenue faster (-5.2% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALKS | PRAX |
|---|---|---|
| Share price | $41.45 | $278.02 |
| Market cap | $6.95B | $7.76B |
| 1-day change | -0.49% | -0.76% |
| YTD return | +48.12% | -5.67% |
| 1-year return | +33.91% | +434.24% |
| 5-year return | +30.87% | -7.37% |
| P/E ratio (TTM) | 109.07 | — |
| Forward P/E | 22.92 | — |
| EPS (TTM) | $0.38 | $-12.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.48B | $0 |
| Revenue growth (YoY) | -5.25% | -100.00% |
| Net income (latest FY) | $241.66M | $-303.27M |
| Gross margin | 86.69% | — |
| Operating margin | 17.21% | — |
| Net margin | 16.37% | — |
| 52-week high | $55.67 | $392.70 |
| 52-week low | $27.00 | $50.56 |
| Distance from 52-week high | -25.55% | -29.20% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +36.47% | +131.79% |
| Average volume | 1.83M | 404.98K |
| Shares outstanding | 167.76M | 27.92M |
| Employees | 2,050 | 168 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed ALKS by 400.3 percentage points over the past year.
- Alkermes grew revenue faster in its latest fiscal year (-5.25% vs -100.00%).
About Alkermes
ALKS stock →Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
ALKS vs PRAX FAQ
Which is bigger, Alkermes or Praxis Precision Medicines?
Praxis Precision Medicines (PRAX) is larger, with a market capitalization of $7.76B compared with $6.95B for Alkermes (ALKS).
Which stock has performed better over the past year, ALKS or PRAX?
PRAX returned +434.24% over the past 12 months, compared with +33.91% for ALKS (price return, excluding dividends). Past performance does not predict future results.
Are Alkermes and Praxis Precision Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.